SWM
RCKT icon

Spire Wealth Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Spire Wealth Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,320
Closed -$16.6K – 2561
2024
Q4 		$16.6K Sell
1,320
-681
-34% -$10.3K ﹤0.01% 1681
2024
Q3 		$37K Buy
+2,001
New +$41K ﹤0.01% 1233

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Spire Wealth Management's RCKT Position: Q1 2025 in Review

Spire Wealth Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 1,320 shares — an estimated $16.6K sold.

Spire Wealth Management first reported a position in RCKT in Q3 2024 and held it in 2 quarters. The position peaked at $37K in Q3 2024. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Spire Wealth Management reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Spire Wealth Management sold 1,320 Rocket Pharmaceuticals shares in Q1 2025, an estimated $16.6K.
  • Spire Wealth Management first reported a position in Rocket Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Spire Wealth Management's Rocket Pharmaceuticals position peaked at $37K in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Spire Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.